The University of Hawaii Cancer Research Center provides cancer related research opportunities for the multi-ethnic population of Hawaii and the Pacific. The Center's multimodal/multidisciplinary clinical faculty strongly endorse participation in the Southwest Oncology Group (SWOG) project which is the major source of peer reviewed clinical trials for the residents of Hawaii. At this time 70% of all patients placed on SWOG trials in Hawaii are non-Caucasian ethnic minorities. Eleven percent of enrollees are National Cancer Institute designated underserved minorities, 45% women and 34% elderly.
One aim of SWOG investigators is to increase overall accrual and the proportion of participating underserved populations. Clinical research and community outreach activities will be aimed at decreasing barriers to care by developing culturally sensitive approaches to treatment and screening. Total accrual to SWOG studies has risen 119% over the past four years and is projected to increase further with a proportionately greater accrual of underserved groups such as native Hawaiians, the socioeconomically disadvantaged, women and the elderly. Another aim is to increase scientific contributions as measured by the coordination of new group studies. This will be achieved as a result of recently recruited full-time faculty with experience in clinical trials, drug development and behavioral/psychosocial science. Progress to date includes: SWOG studies of dose intensification with growth factors, surgery and pathology leadership of an Intergroup adjuvant gastric cancer trial, innovative Phase II SWOG gastric cancer trials, and several Center pilot studies which will be proposed for SWOG participation if results are promising. A further aim is to improve data management. Increased staffing and organizational changes to handle increased patient registrations and follow up have been implemented and show substantial improvements. The University of Hawaii SWOG project will provide valuable information on the conduct of clinical trials in ethnic minorities and underserved groups. This will be relevant both to the population of Hawaii and to populations elsewhere.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA032734-13
Application #
3557285
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1982-09-01
Project End
1994-07-31
Budget Start
1994-01-01
Budget End
1994-07-31
Support Year
13
Fiscal Year
1994
Total Cost
Indirect Cost
Name
University of Hawaii
Department
Type
Organized Research Units
DUNS #
121911077
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Tangen, Catherine M; Hussain, Maha H A; Higano, Celestia S et al. (2012) Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol 188:1164-9
Scosyrev, Emil; Ely, Benjamin W; Messing, Edward M et al. (2011) Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 108:693-9
Albain, Kathy S; Barlow, William E; Shak, Steven et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
Albain, Kathy S; Barlow, William E; Ravdin, Peter M et al. (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:2055-63
Sonpavde, Guru; Goldman, Bryan H; Speights, V O et al. (2009) Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115:4104-9
Beer, Tomasz M; Tangen, Catherine M; Bland, Lisa B et al. (2006) The prognostic value of hemoglobin change after initiating androgen-deprivation therapy for newly diagnosed metastatic prostate cancer: A multivariate analysis of Southwest Oncology Group Study 8894. Cancer 107:489-96
Hutchins, Laura F; Green, Stephanie J; Ravdin, Peter M et al. (2005) Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-010 J Clin Oncol 23:8313-21
Whitehead, Robert P; Benedetti, Jacqueline K; Abbruzzese, James L et al. (2004) A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study. Invest New Drugs 22:467-73
Arpino, Grazia; Green, Stephanie J; Allred, D Craig et al. (2004) HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 10:5670-6

Showing the most recent 10 out of 24 publications